GA NCORP

Treatment Sites

Piedmont Columbus Regional

The John B. Amos Cancer Center is a multi-disciplinary cancer center accredited by the Commission on Cancer of the American College of Surgeons as a Community Hospital Comprehensive Cancer Program – the only treatment center to be so named in the 14-county service area of Columbus, Georgia. The center is also accredited by the American College of Radiology (ACR). The John B. Amos Cancer Center is a recipient of the Georgia Cancer Coalition Distinguished Cancer Scholars Award, which supports leaders who are engaged in the most promising areas of cancer research. John B. Amos is a member of the Atlanta Regional Community Clinical Oncology Program (ARCCOP), a program initiated by the National Cancer Institute (NCI) to provide community hospitals access to a wide range of clinical research studies. The center is also a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers and a member of the Georgia CORE Gynecologic Oncology Group Consortium. The center consists of eleven physicians with three clinics: medical oncology, gynecologic oncology and radiation oncology. The John B. Amos Cancer Center offers a medical team of experienced board-certified oncologists (MDs), advanced registered nurse practitioners, clinical researchers, case manager associates, clinical counselors, pharmacists, radiation physicists and therapists, oncology- and chemotherapy-certified nurses and registered dietitians.

Treatment Sites


Primary Location

1831 5th Ave
Columbus, GA 31901
706-320-8700 (p)
www.columbusregional.com

driving directions

Clinical Trials

Connect® Myeloid Disease Registry
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Cancer Type: Lung Cancer
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Lung Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Bladder Cancer, Brain & Spinal Cord Tumor, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Plasma cell neoplasm, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Thyroid Cancer, Unknown Primary, Uterine Cancer
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426